Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02758808 · ClinicalTrials.gov registry record
Pulmonary Fibrosis Foundation Patient Registry
A clinical trial, sponsored by Pulmonary Fibrosis Foundation.
- Completed
- Registry status
- 2,004
- Enrollment target
NCT02758808: Completed study, sponsored by Pulmonary Fibrosis Foundation.
NCT02758808 is a clinical trial that has completed, run by Pulmonary Fibrosis Foundation. The registered enrollment target is 2,004 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02758808 has completed, sponsored by Pulmonary Fibrosis Foundation.
- COMPLETED
- Registry status
- 2,004 participants
- Enrollment target
Study Summary
The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research
Primary Outcome
Analysis of registry data will lead to aggregated reports summarizing the pulmonary function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,004 participants |
| Start Date | 2016-03-29 |
| Est. Completion | 2022-12-16 |
What the finished NCT02758808 record still lists
NCT02758808 is an observational study that tracks outcomes without assigning an intervention. Its 2,004 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02758808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02758808 about?
NCT02758808 is a clinical study titled "Pulmonary Fibrosis Foundation Patient Registry". The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibr...
What is the current status of trial NCT02758808?
This trial is currently completed. The enrollment target is 2,004 participants. The study started on 2016-03-29. Estimated completion is 2022-12-16.
Who is sponsoring clinical trial NCT02758808?
This trial is sponsored by Pulmonary Fibrosis Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI